{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T21:36:35Z","timestamp":1769549795370,"version":"3.49.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Research Council of Norway","doi-asserted-by":"publisher","award":["223273\/F50"],"award-info":[{"award-number":["223273\/F50"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007793","name":"Stiftelsen Kristian Gerhard Jebsen","doi-asserted-by":"publisher","award":["SKGJ-MED-008"],"award-info":[{"award-number":["SKGJ-MED-008"]}],"id":[{"id":"10.13039\/100007793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1093\/ijnp\/pyz012","type":"journal-article","created":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T21:27:09Z","timestamp":1551907629000},"page":"358-369","source":"Crossref","is-referenced-by-count":16,"title":["One-Year Treatment with Olanzapine Depot in Female Rats: Metabolic Effects"],"prefix":"10.1093","volume":"22","author":[{"given":"Kari M","family":"Ersland","sequence":"first","affiliation":[{"name":"The Norwegian Centre for Mental Disorders Research (NORMENT), Department of Clinical Science, University of Bergen, Norway"},{"name":"Dr. Einar Martens\u2019 Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene S","family":"Myrmel","sequence":"additional","affiliation":[{"name":"Institute of Marine Research, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Even","family":"Fj\u00e6re","sequence":"additional","affiliation":[{"name":"Institute of Marine Research, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolf K","family":"Berge","sequence":"additional","affiliation":[{"name":"The Lipid Research Group, Section for Medical Biochemistry, Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Madsen","sequence":"additional","affiliation":[{"name":"Institute of Marine Research, Bergen, Norway"},{"name":"Department of Biology, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidar M","family":"Steen","sequence":"additional","affiliation":[{"name":"The Norwegian Centre for Mental Disorders Research (NORMENT), Department of Clinical Science, University of Bergen, Norway"},{"name":"Dr. Einar Martens\u2019 Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silje","family":"Skrede","sequence":"additional","affiliation":[{"name":"The Norwegian Centre for Mental Disorders Research (NORMENT), Department of Clinical Science, University of Bergen, Norway"},{"name":"Dr. Einar Martens\u2019 Research Group for Biological Psychiatry, Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,3,3]]},"reference":[{"key":"2019050311422267600_CIT0001","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/mp.2010.33","article-title":"Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis","volume":"16","author":"Albaugh","year":"2011","journal-title":"Mol Psychiatry"},{"key":"2019050311422267600_CIT0002","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/schbul\/sbq053","article-title":"Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents","volume":"38","author":"Albaugh","year":"2012","journal-title":"Schizophr Bull"},{"key":"2019050311422267600_CIT0003","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1017\/S0007114509990729","article-title":"Experimental rat models to study the metabolic syndrome","volume":"102","author":"Aleixandre de Artinano","year":"2009","journal-title":"Br J Nutr"},{"key":"2019050311422267600_CIT0004","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1099-081X(199911)20:8<369::AID-BDD200>3.0.CO;2-6","article-title":"Pharmacokinetics and tissue distribution of olanzapine in rats","volume":"20","author":"Aravagiri","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"2019050311422267600_CIT0005","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1007\/s00213-016-4324-8","article-title":"Atypical antipsychotics and effects on feeding: from mice to men","volume":"233","author":"Benarroch","year":"2016","journal-title":"Psychopharmacology (Berl)"},{"key":"2019050311422267600_CIT0006","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2017.10.030","article-title":"Rates and predictors of relapse following discontinuation of antipsychotic medication after a first episode of psychosis","volume":"195:","author":"Bowtell","year":"2017","journal-title":"Schizophr Res"},{"key":"2019050311422267600_CIT0007","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.tips.2010.07.002","article-title":"Preclinical models of antipsychotic drug-induced metabolic side effects","volume":"31","author":"Boyda","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"2019050311422267600_CIT0008","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.psyneuen.2018.05.021","article-title":"Effects of chronic antipsychotic drug exposure on the expression of translocator protein and inflammatory markers in rat adipose tissue","volume":"95","author":"Calevro","year":"2018","journal-title":"Psychoneuroendocrinology"},{"key":"2019050311422267600_CIT0009","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.schres.2008.06.006","article-title":"Insulin resistance following continuous, chronic olanzapine treatment: an animal model","volume":"104","author":"Chintoh","year":"2008","journal-title":"Schizophr Res"},{"key":"2019050311422267600_CIT0010","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/wps.20204","article-title":"Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder","volume":"14","author":"Correll","year":"2015","journal-title":"World Psychiatry"},{"key":"2019050311422267600_CIT0011","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/wps.20420","article-title":"Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls","volume":"16","author":"Correll","year":"2017","journal-title":"World Psychiatry"},{"key":"2019050311422267600_CIT0012","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1177\/0269881115602490","article-title":"Antipsychotic-induced metabolic effects in the female rat: direct comparison between long-acting injections of risperidone and olanzapine","volume":"29","author":"Ersland","year":"2015","journal-title":"J Psychopharmacol"},{"key":"2019050311422267600_CIT0013","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41398-017-0008-3","article-title":"Subchronic olanzapine exposure leads to increased expression of myelination-related genes in rat fronto-medial cortex","volume":"7","author":"Ersland","year":"2017","journal-title":"Transl Psychiatry"},{"key":"2019050311422267600_CIT0014","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00213-008-1370-x","article-title":"Acute clozapine exposure in vivo induces lipid accumulation and marked sequential changes in the expression of SREBP, PPAR, and LXR target genes in rat liver","volume":"203","author":"Fern\u00f8","year":"2009","journal-title":"Psychopharmacology"},{"key":"2019050311422267600_CIT0015","doi-asserted-by":"crossref","first-page":"e20571","DOI":"10.1371\/journal.pone.0020571","article-title":"Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation","volume":"6","author":"Fern\u00f8","year":"2011","journal-title":"Plos One"},{"key":"2019050311422267600_CIT0016","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.euroneuro.2015.03.002","article-title":"Olanzapine depot exposure in male rats: dose-dependent lipogenic effects without concomitant weight gain","volume":"25","author":"Fern\u00f8","year":"2015","journal-title":"Eur Neuropsychopharmacol"},{"key":"2019050311422267600_CIT0017","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/026988110201600402","article-title":"Characterization of olanzapine-induced weight gain in rats","volume":"16","author":"Goudie","year":"2002","journal-title":"J Psychopharmacol"},{"key":"2019050311422267600_CIT0018","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.psyneuen.2008.01.018","article-title":"Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression","volume":"33","author":"Han","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"2019050311422267600_CIT0019","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.psyneuen.2016.07.218","article-title":"Olanzapine-depot administration induces time-dependent changes in adipose tissue endocrine function in rats","volume":"73","author":"Horska","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"2019050311422267600_CIT0020","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.neuropharm.2017.06.003","article-title":"Aripiprazole-induced adverse metabolic alterations in polyi:C neurodevelopmental model of schizophrenia in rats","volume":"123","author":"Horska","year":"2017","journal-title":"Neuropharmacology"},{"key":"2019050311422267600_CIT0021","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/sj.npp.1301209","article-title":"Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects","volume":"32","author":"Houseknecht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"2019050311422267600_CIT0022","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00213-011-2397-y","article-title":"Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat","volume":"219","author":"Jassim","year":"2012","journal-title":"Psychopharmacology (Berl)"},{"key":"2019050311422267600_CIT0023","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00213-005-0081-9","article-title":"Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats","volume":"182","author":"Kalinichev","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"key":"2019050311422267600_CIT0024","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1176\/appi.ajp.2009.07081221","article-title":"Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia","volume":"167","author":"Kane","year":"2010","journal-title":"Am J Psychiatry"},{"key":"2019050311422267600_CIT0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1124\/jpet.102.046987","article-title":"Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy","volume":"305","author":"Kapur","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"2019050311422267600_CIT0026","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019050311422267600_CIT0027","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"2019050311422267600_CIT0028","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"2019050311422267600_CIT0029","doi-asserted-by":"crossref","first-page":"e0148539","DOI":"10.1371\/journal.pone.0148539","article-title":"Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor clinical efficacy in patients with schizophrenia","volume":"11","author":"Lu","year":"2016","journal-title":"Plos One"},{"key":"2019050311422267600_CIT0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/epirev\/mxn001","article-title":"Schizophrenia: a concise overview of incidence, prevalence, and mortality","volume":"30","author":"McGrath","year":"2008","journal-title":"Epidemiol Rev"},{"key":"2019050311422267600_CIT0031","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1038\/tp.2012.138","article-title":"Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways","volume":"3","author":"Mondelli","year":"2013","journal-title":"Transl Psychiatry"},{"key":"2019050311422267600_CIT0032","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bjc.1981.100","article-title":"Characteristics of 106 spontaneous mammary tumours appearing in sprague-dawley female rats","volume":"43","author":"Okada","year":"1981","journal-title":"Br J Cancer"},{"key":"2019050311422267600_CIT0033","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pbb.2011.07.019","article-title":"Modeling chronic olanzapine exposure using osmotic minipumps: pharmacological limitations","volume":"100","author":"Remington","year":"2011","journal-title":"Pharmacol Biochem Behav"},{"key":"2019050311422267600_CIT0034","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment\u2013pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol Ther"},{"key":"2019050311422267600_CIT0035","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1520\/JFS14697J","article-title":"Olanzapine concentrations in clinical serum and postmortem blood specimens\u2013when does therapeutic become toxic","volume":"45","author":"Robertson","year":"2000","journal-title":"J Forensic Sci"},{"key":"2019050311422267600_CIT0036","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.carpath.2006.09.001","article-title":"Small animal models of cardiovascular disease: tools for the study of the roles of metabolic syndrome, dyslipidemia, and atherosclerosis","volume":"15","author":"Russell","year":"2006","journal-title":"Cardiovasc Pathol"},{"key":"2019050311422267600_CIT0037","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.schres.2006.09.018","article-title":"The association of insight with psychotic symptoms, depression, and cognition in early psychosis: a 3-year follow-up","volume":"89","author":"Saeedi","year":"2007","journal-title":"Schizophr Res"},{"key":"2019050311422267600_CIT0038","first-page":"624","article-title":"The laboratory rat: relating its age with human\u2019s","volume":"4","author":"Sengupta","year":"2013","journal-title":"Int J Prev Med"},{"key":"2019050311422267600_CIT0039","doi-asserted-by":"crossref","first-page":"e50853","DOI":"10.1371\/journal.pone.0050853","article-title":"Lipid-lowering effects of tetradecylthioacetic acid in antipsychotic-exposed, female rats: challenges with long-term treatment","volume":"7","author":"Skrede","year":"2012","journal-title":"Plos One"},{"key":"2019050311422267600_CIT0040","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1017\/S1461145711001271","article-title":"Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats","volume":"15","author":"Skrede","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"2019050311422267600_CIT0041","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1017\/S1461145713000862","article-title":"Olanzapine depot formulation in rat: a step forward in modelling antipsychotic-induced metabolic adverse effects","volume":"17","author":"Skrede","year":"2014","journal-title":"Int J Neuropsychopharmacol"},{"key":"2019050311422267600_CIT0042","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/JCP.0000000000000961","article-title":"Age impacts olanzapine exposure differently during use of oral versus long-acting injectable formulations: an observational study including 8,288 patients","volume":"38","author":"Tveito","year":"2018","journal-title":"J Clin Psychopharmacol"},{"key":"2019050311422267600_CIT0043","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0022-2275(20)41285-4","article-title":"Age-related changes in cholesterol and bile acid metabolism in rats","volume":"19","author":"Uchida","year":"1978","journal-title":"J Lipid Res"},{"key":"2019050311422267600_CIT0044","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.schres.2017.11.007","article-title":"Who needs antipsychotic maintenance treatment and who does not? Our need to profile and personalize the treatment of first episode psychosis","volume":"197:","author":"Wunderink","year":"2017","journal-title":"Schizophr Res"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/22\/5\/358\/28557245\/pyz012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T03:02:55Z","timestamp":1663038175000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/22\/5\/358\/5373084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,3]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,3,3]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyz012","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2019,3,3]]}}}